解剖学和形态学
麻醉学
听力与言语-语言病理学
行为科学
心脏和心血管系统
细胞和组织工程学
临床神经病学
危重症监护医学
牙科,口腔外科和医学
皮肤病学
急诊医学
内分泌学和新陈代谢
肠胃学和肝脏学
老人病学和老年医学
卫生保健科学和服务
血液学
免疫学
传染病
综合和补充性医学
医学伦理学
医学信息学
医学实验室技术
医学,全科和内科
医学,法律
医学,研究和试验
神经系统科学
护理
营养学和饮食学
产科医学和妇科医学
肿瘤学
眼科学
整形外科学
耳鼻喉科学
病理学
儿科学
周围血管疾病
药理学和药剂学
生理学
基本医疗保健
精神病学
公共、环境和职业卫生
放射学,核医学和医学成像
康复学
生殖生物学
呼吸系统
风湿病学
运动科学
外科学
毒理学
热带医学
泌尿学和肾脏学
病毒学
老年医学
健康政策和服务
心理学,临床
abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2786
更新日期:2020-12-01 00:00:00
abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2761
更新日期:2020-12-01 00:00:00
abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2724
更新日期:2020-10-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...
journal_title:Hematological oncology
pub_type: 杂志文章,随机对照试验
doi:10.1002/hon.2750
更新日期:2020-10-01 00:00:00
abstract::Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2772
更新日期:2020-10-01 00:00:00
abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2775
更新日期:2020-10-01 00:00:00
abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2811
更新日期:2020-09-26 00:00:00
abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2809
更新日期:2020-09-25 00:00:00
abstract::Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2793
更新日期:2020-08-27 00:00:00
abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2711
更新日期:2020-08-01 00:00:00
abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2729
更新日期:2020-08-01 00:00:00
abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2676
更新日期:2020-02-01 00:00:00
abstract::This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2704
更新日期:2020-02-01 00:00:00
abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2646
更新日期:2019-10-01 00:00:00
abstract::The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2670
更新日期:2019-10-01 00:00:00
abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2652
更新日期:2019-10-01 00:00:00
abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2647
更新日期:2019-10-01 00:00:00
abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2635
更新日期:2019-08-01 00:00:00
abstract::Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2585
更新日期:2019-06-01 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2572
更新日期:2019-04-01 00:00:00
abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2547
更新日期:2019-02-01 00:00:00
abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2522
更新日期:2018-12-01 00:00:00
abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2515
更新日期:2018-10-01 00:00:00
abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2532
更新日期:2018-10-01 00:00:00
abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2520
更新日期:2018-10-01 00:00:00
abstract::Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2500
更新日期:2018-04-01 00:00:00
abstract::Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2493
更新日期:2018-04-01 00:00:00
abstract::The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2504
更新日期:2018-02-27 00:00:00
abstract::Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2457
更新日期:2018-02-01 00:00:00
abstract::Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2483
更新日期:2018-02-01 00:00:00
abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2427
更新日期:2018-02-01 00:00:00
abstract::The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2423
更新日期:2018-02-01 00:00:00
abstract::These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2454
更新日期:2018-02-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2344
更新日期:2017-12-01 00:00:00
abstract::Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2326
更新日期:2017-12-01 00:00:00
abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2368
更新日期:2017-12-01 00:00:00
abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...
journal_title:Hematological oncology
pub_type:
doi:10.1002/hon.2376
更新日期:2017-12-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2298
更新日期:2017-09-01 00:00:00
abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2279
更新日期:2017-09-01 00:00:00